(Q46062872)

19 December 2017

title

Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease (English)

1 reference

19 December 2017

1 reference

2

1 reference

19 December 2017

Karl-Norbert Klotz

7

1 reference

19 December 2017

Maria Letizia Trincavelli

8

1 reference

19 December 2017

Claudia Martini

9

1 reference

19 December 2017

Gloria Cristalli

10

object named as

Gloria Cristalli

1 reference

19 December 2017

author name string

Rosaria Volpini

1

1 reference

19 December 2017

Catia Lambertucci

3

1 reference

19 December 2017

Gabriella Marucci

4

1 reference

19 December 2017

Ram Chandra Mishra

5

1 reference

19 December 2017

Anna Teresa Ramadori

6

1 reference

19 December 2017

publication date

1 June 2009

1 reference

19 December 2017

published in

ChemMedChem

1 reference

19 December 2017

volume

4

1 reference

19 December 2017

issue

6

1 reference

19 December 2017

page(s)

1010-1019

1 reference

19 December 2017

Adenosine receptors as therapeutic targets

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Medicinal chemistry of adenosine A1 receptor ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Adenosine, an endogenous distress signal, modulates tissue damage and repair

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Adenosine receptors and their ligands.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Adenosine receptors: new opportunities for future drugs.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

New substituted 9-alkylpurines as adenosine receptor ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Medicinal chemistry and pharmacology of A2B adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

2- and 8-alkynyl-9-ethyladenines: Synthesis and biological activity at human and rat adenosine receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Aspects of the general biology of adenosine A2A signaling.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Highlights on the development of A(2A) adenosine receptor agonists and antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

New adenosine A2A receptor antagonists: actions on Parkinson's disease models

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

MOPAC: a semiempirical molecular orbital program

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800434

7 January 2021

Identifiers

DOI

10.1002/CMDC.200800434

1 reference

19 December 2017

1 reference

19 December 2017